Value Quest Platinum PMS Review: Performance, Fees & Should You Stay Invested?
| What Works | What Doesn’t |
|---|---|
| Since-inception CAGR of 17.93% comfortably beats the benchmark’s 12.69% — a genuine 11-year, 9-month track record | Standard deviation of 16.40% vs benchmark’s 13.91% — you are carrying meaningfully more volatility, and the 1-year return of -4.65% shows exactly how that volatility feels in a bad stretch |
| 5-year CAGR of 15.35% vs benchmark’s 12.29% — outperformance that holds up across multiple cycles, not just one lucky year | 53.72% small-cap concentration in an 8-12 stock portfolio means a handful of names carry an outsized share of your outcome — both up and down |
| Sharpe Ratio of 0.76 vs benchmark’s 0.60 and Jensen Alpha of 4.44 — the outperformance is statistically real, not a rounding artifact | ₹25 crore minimum investment and 2.5% fixed fee plus profit sharing mean the cost of being wrong here is also outsized |
Verdict: The numbers here are genuinely strong — stronger than most PMS portfolios you will review.
But strong historical numbers and the right decision for you, right now are two different questions.
This article walks through both, honestly.
Key Facts
| Strategy | ValueQuest Platinum — PMS |
| Benchmark | BSE 500 TRI |
| Inception Date | July 24, 2014 |
| Fund Manager | Ravi Dharamshi, 23 years of experience |
| Strategy AUM | ₹3,167 crore |
| Firm wide AUM | ₹27,925 crore (~$2.94 billion) |
| Total Stocks | 22 (factsheet) / 8-12 core concentrated positions (stated mandate) |
| Minimum Investment | ₹25 crore |
| Fixed Fee | 2.5% p.a. |
| Variable Fee | 1.5% AMC + 15% profit sharing above 10% hurdle |
| Exit Load | 1% (Years 1-3), Nil thereafter |
| Market Cap Mix | Large Cap: 21.01% / Mid Cap: 22.33% / Small Cap: 53.72% / Cash: 2.94% |
The stated mandate is refreshingly specific: A Multicap, sector-agnostic strategy built around 8 to 12 high-conviction stocks, with a low tolerance for sustained underperformance and a genuine appetite for young, new-to-market, and turnaround businesses.
The investment framework — large addressable opportunity, sustainable competitive advantage, scalable business model, management integrity, and valuation margin of safety — reads like a genuine philosophy, not a marketing slide.
And here is the part that deserves real credit: the data backs up the philosophy.
This is not a strategy quietly hugging the benchmark while charging an active fee.
At 53.72% small-cap and structured around 8-12 stocks, the portfolio looks nothing like a diversified mutual fund.
You are not paying 2.5% for index-like exposure dressed up as alpha.
You are paying for a genuinely concentrated, genuinely differentiated bet.
So where is the catch? It is not in the mandate.
It is in what concentration costs you when the cycle turns — and whether you, specifically, are positioned to absorb that cost.
When did you last actually sit down and look at this portfolio’s returns across every period — not just the headline since-inception number that anchors every conversation about this strategy?
Trailing Returns (as on May 31, 2026)
| Period | VQ Platinum | BSE 500 TRI | Alpha (+/-) |
|---|---|---|---|
| 1 Month | -0.71% | -0.17% | -0.54% |
| 3 Months | 4.43% | -2.34% | +6.77% |
| 6 Months | -1.94% | -5.39% | +3.45% |
| 1 Year | -4.65% | -0.07% | -4.58% |
| 2 Years (CAGR) | 3.28% | 4.14% | -0.86% |
| 3 Years (CAGR) | 13.61% | 13.46% | +0.15% |
| 5 Years (CAGR) | 15.35% | 12.29% | +3.06% |
| 10 Years (CAGR) | 17.71% | 14.03% | +3.68% |
| Since Inception (CAGR) | 17.93% | 12.69% | +5.24% |
Performance figures are net of all fees and expenses. TWRR basis.
Calendar Year Performance
| Year | VQ Platinum | Notes |
|---|---|---|
| CY 2014 | 17.48% | Partial year, post-inception |
| CY 2016 | 25.5% | |
| CY 2018 | -4.22% | |
| CY 2020 | 28.95% | |
| CY 2021 | -7.92% | |
| CY 2022 | -0.5% | |
| CY 2023 | 42.01% | Strong recovery |
| CY 2024 | 65.6% | Exceptional year |
| CY 2025 | 53.3% | |
| CY 2026 YTD | 31.12% / -13.39% (trailing) / 3.15% | Mixed signals — see note below |
Here is what the data is actually telling you.
Let’s be honest about what the trailing returns show.
Over 1 year, you are down 4.65% while the benchmark is essentially flat.
That is not a small gap, and if this is the number you’ve been staring at recently, your unease is justified — the data agrees with your gut.
The 2-year number also trails the benchmark slightly.
This is real, and it deserves acknowledgment rather than being buried under the more flattering since-inception figure.
But wait — look at this more carefully.
The 3-month return of 4.43% against a falling benchmark of -2.34%, and the 6-month figure of -1.94% against -5.39%, suggest the portfolio has been clawing back ground in the most recent stretch.
The pattern across the calendar years tells a similar story: 2021 and 2022 were genuinely difficult (-7.92% and -0.5%), followed by an extraordinary run in 2023-2025 (42.01%, 65.6%, 53.3%).
This is a strategy that has historically moved in pronounced cycles — sharp drawdowns followed by sharp recoveries — rather than a smooth, steady compounding line.
Is the recent -4.65% one-year number a style headwind or something more structural? The evidence leans toward style cycle.
Small and midcap-heavy, concentrated portfolios like this one are inherently more sensitive to risk-on, risk-off sentiment shifts than the broader index.
When liquidity tightens or risk appetite contracts, concentrated small-cap books get hit disproportionately — and that appears to be exactly what happened in the most recent 12-month window, even as the 3-year, 5-year, and 10-year numbers remain firmly ahead of the benchmark.
Here’s the question that actually matters for you: are you the kind of investor who can look at a -4.65% year, understand it within the context of a strategy that has delivered 17.93% annualised since 2014, and hold steady? Or does that number sit in your stomach differently than it sits on a spreadsheet?
Let’s talk about what 2.5% plus profit sharing actually costs you — and whether the numbers justify it.
The PMS Value Framework
Gross Alpha > Fee = Value Added Gross Alpha ≈ Fee = Break-Even Gross Alpha < Fee = Value Destroyed
Here is where this review differs from most you will read. Applying this framework to the 5-year window: net alpha is +3.06% per annum, already after the fee has left your account.
The gross alpha — before the 2.5% fee — is therefore approximately 5.56% per annum.
The fee consumed roughly 45% of the value generated, and you still walked away with a meaningful, positive net edge over the benchmark.
Over the since-inception period, the picture is stronger still: net alpha of +5.24% per annum, with gross alpha before fees of approximately 7.74%.
This places ValueQuest Platinum in the value-added zone — one of the few PMS strategies where the fee, while substantial, has historically been earned rather than simply extracted.
The honest caveat: the most recent 1-year and 2-year windows sit closer to the break-even-to-value-destroyed zone, with negative net alpha.
The framework is not static — it has to be re-applied at every point you choose to evaluate it.
The question you need to ask is not “has this fee been justified historically” but “is it being justified right now, in the period I am actually living through.”
Fee Drag on ₹50 Lakhs: The Rupee Picture
| Scenario | Gross Return Assumed (Estimated) | Corpus After 5 Years | Corpus After 7 Years |
|---|---|---|---|
| VQ Platinum (Net, 5Y CAGR) | ~17.85% gross | ₹1.02 crore | ₹1.55 crore |
| Active Flexi-Cap MF (category median ~15%) | 15% | ₹1.00 crore | ₹1.38 crore |
| Passive Index Fund (BSE 500 TRI, 0.15% fee) | 12.29% | ₹89.7 lakhs | ₹1.25 crore |
Calculations use CAGR compounding on ₹50 lakhs initial corpus. Net-of-fee returns used for all scenarios.
On a ₹50 lakh allocation, the 5-year gap between this strategy and a passive index fund is approximately ₹12.3 lakhs in your favour.
Over 7 years, that widens to roughly ₹30 lakhs.
That is a real, tangible number — and unlike many PMS reviews you will read, this one shows the fee actually being earned back with room to spare.
But here is the part that deserves your full attention: this table uses the 5-year CAGR, which smooths over the recent -4.65% year.
If your specific entry point was 12-18 months ago, your personal experience does not look like this table.
It looks closer to the 1-year and 2-year columns in the performance table above — and those numbers tell a meaningfully different story.
The rupee picture is only as good as the period you actually lived through, not the period that looks best on a factsheet.
This is the most important section in this article. Read it slowly, and answer it honestly — not for the article, but for yourself.
Knowing everything you know today, if you were starting fresh with this same ₹25 crores — would you invest it in ValueQuest Platinum right now?
Notice what that question does and does not ask. It does not ask whether the historical returns are good. They are.
It does not ask whether the fund manager is skilled.
The evidence suggests he is. It asks something narrower and more honest: given the current portfolio — 53.72% small-cap, 8-12 concentrated positions, a -4.65% trailing year, a standard deviation nearly 18% higher than the benchmark — is this the risk you would choose to take on, today, with fresh eyes and no history?
If your answer is an unhesitating yes, that is a meaningful signal.
It means your conviction is current, not just inherited from a decision you made years ago. Hold the position with confidence.
But if you hesitate — if the honest answer is “I’m not sure, but I’ve already been in this for years so I’ll just stay” — that hesitation is worth sitting with.
Staying invested because you already are invested is not a strategy. It is inertia wearing the costume of conviction.
Here is the asymmetry that matters: exiting a position you no longer have full conviction in is not an admission of failure.
It is not even an admission that the original decision was wrong — markets change, your life circumstances change, and a concentrated small-cap strategy that made sense for you in 2019 may not make sense for you in 2026 if your time horizon has shortened or your risk tolerance has genuinely evolved.
The decision to stay invested is the one that requires fresh justification — not the decision to leave.
So ask yourself plainly: would you sign this same agreement today, for the first time, knowing what the last 12 months actually felt like? If yes, you have your answer.
If you are still working it out, that uncertainty itself is information you should not ignore.
| Decision Factor | Rating | Analysis |
|---|---|---|
| Uniqueness vs existing MF portfolio | 🟢 Pass | This is genuinely where ValueQuest Platinum earns its place. At 53.72% small-cap and built around 8-12 concentrated positions, the portfolio does not resemble the holdings inside a typical flexi-cap or large-cap mutual fund. Names like Apar Industries, Concord Biotech, Home First Finance, and Tenneco Clean Air India are not the household large-cap names that dominate most diversified mutual fund portfolios. If your core holdings are index funds or large-cap-oriented mutual funds, this strategy is very likely accessing stocks and segments you simply do not own elsewhere. That said, you should still check — not assume — whether any other midcap or smallcap fund you hold creates overlap with these specific names. |
| Alpha consistency across all periods | 🟡 Mixed | Across 3-year, 5-year, 10-year, and since-inception windows, the alpha is real and consistent — +0.15%, +3.06%, +3.68%, and +5.24% respectively. That is a genuinely strong multi-cycle record. But the 1-year (-4.58%) and 2-year (-0.86%) numbers tell you that the most recent stretch has not continued this pattern. Is this is a temporary air pocket in an otherwise strong trend, or the early signs of a longer rough patch? The honest answer is that one bad year inside an 11-year track record is not unusual for a concentrated small-cap strategy — the calendar year data shows similar drawdown years in 2018, 2021, and 2022, each followed by recovery. The pattern suggests cyclicality rather than structural decay, but you should not dismiss the recent numbers simply because the longer history is reassuring. |
| Justification for PMS premium fee | 🟢 Pass | Over the 5-year and since-inception periods, the net alpha generated — 3.06% and 5.24% respectively — comfortably exceeds what you would expect to pay in fee drag, and the gross-to-net fee analysis places this strategy in the value-added zone rather than break-even or value-destroyed. This is one of the few PMS reviews where the fee genuinely appears to have been earned over a multi-year horizon. The caveat, stated plainly: the most recent 1-2 year window does not support this same conclusion, and if your personal holding period is shorter, your lived experience of fee justification will look different from the long-term average. |
| Downside protection in market corrections | 🔴 Concern | This is the most honest concern in this entire review. A standard deviation of 16.40% against the benchmark’s 13.91%, combined with a -4.65% one-year return while the benchmark is essentially flat, tells you plainly that this strategy does not protect capital during corrections — it amplifies the move, in both directions. Calendar years 2018 (-4.22%), 2021 (-7.92%), and the recent 1-year figure all confirm this pattern. The strategy is not designed as a defensive vehicle, and you should not expect it to behave like one. If capital preservation during drawdowns is a priority for you, this is the single most important data point in the entire review. |
| Portfolio complement for MF investor | 🟢 Pass | With its heavy small-cap tilt (53.72%) and genuinely concentrated structure, this strategy can function as a true satellite allocation rather than a duplicate of your core mutual fund holdings — provided your core is built around large-cap, flexi-cap, or index exposure. The complementarity breaks down only if you already hold other small-cap-heavy PMS, AIF, or mutual fund strategies, in which case you may be stacking concentrated small-cap risk across multiple vehicles without realising it. |
| Mandate purity and discipline | 🟢 Pass | The stated mandate — 8-12 concentrated stocks, Multicap, sector-agnostic, low tolerance for underperformance — is reflected in the actual portfolio composition. There is no evidence of the fund manager quietly drifting toward large-cap comfort or closet-indexing to reduce career risk, which is a real temptation many PMS managers succumb to after a difficult year. The portfolio’s continued tilt toward small caps even after a -4.65% year suggests genuine conviction rather than performance-chasing or panic-driven reallocation. |
| Fund manager transparency | 🟡 Mixed | The factsheet provides detailed portfolio statistics — standard deviation, beta, Sharpe ratio, Jensen Alpha — which is more rigorous disclosure than most PMS factsheets offer. The investment framework is clearly articulated. However, the documents available do not include detailed stock-level entry and exit rationale of the kind some peer strategies publish monthly, which would help you understand the specific thesis behind individual position changes in real time, rather than only at a portfolio-statistics level. |
| Investment horizon suitability | 🟡 Mixed | The strategy explicitly states a 3-year investment horizon, and the data broadly supports this over a 3-year+ window. But the 1-year and 2-year figures are a useful reminder that “3 years” is a minimum, not a guarantee of smooth outcomes even within that window. If your personal financial timeline has compressed — if ₹25 crore that once had a 7-10 year runway now has a 2-3 year runway because of a life change — the horizon that made sense when you invested may no longer match the horizon you actually have today. |
| Market cap flexibility utilisation | 🟢 Pass | The mandate is genuinely multicap and sector-agnostic, and the current allocation — 21.01% large cap, 22.33% midcap, 53.72% small cap — shows the fund manager actively using that flexibility rather than defaulting to a static large-cap-heavy book. This is a real point in the strategy’s favour: many “multicap” PMS strategies behave like large-cap funds in practice. This one does not. |
| Concentration vs diversification balance | 🔴 Concern | An 8-12 stock target, even within a 22-stock disclosed portfolio, with the top 5 holdings comprising 43.44% and the top 5 sectors comprising 91.86% of the book, represents a genuinely concentrated bet. Concentration is the deliberate engine of this strategy’s alpha — and it has worked, historically. But concentration is a double-edged tool: it is also the most likely explanation for both the spectacular years (CY 2024: 65.6%) and the difficult ones (CY 2021: -7.92%, the trailing 1-year: -4.65%). You should not think of this as a diversified equity allocation. Think of it as a small number of high-conviction bets, and size your overall portfolio exposure accordingly. |
| AUM size and strategy capacity | 🟡 Mixed | At ₹3,167 crore in strategy AUM with a 53.72% small-cap allocation, capacity is a real and growing consideration. Small-cap stocks have inherent liquidity ceilings, and as this strategy’s AUM has grown over 11+ years, the fund manager’s ability to build and exit positions in his preferred small-cap names without materially moving the price becomes structurally harder. This is not a current red flag, but it is a trend worth monitoring — concentrated small-cap strategies tend to face capacity constraints precisely when they have been most successful, because success attracts more capital into the same limited pool of investable small-cap opportunities. |
| Manager tenure and continuity risk | 🟢 Pass | Ravi Dharamshi has 23 years of market experience and has managed this specific strategy since its 2014 inception — nearly 12 years of continuous stewardship through multiple market cycles, including the 2018, 2020, and 2021-2022 drawdowns. There is no evidence of recent manager transition or key-person disruption. This long, uninterrupted tenure through both strong and weak periods is a meaningful point of stability, and it means the track record you are evaluating genuinely reflects one person’s process — not a strategy that changed hands and inherited someone else’s history. |
| Decision Factor | Rating |
|---|---|
| Uniqueness vs existing MF portfolio | 🟢 |
| Alpha consistency across all periods | 🟡 |
| Justification for PMS premium fee | 🟢 |
| Downside protection in market corrections | 🔴 |
| Portfolio complement for MF investor | 🟢 |
| Mandate purity and discipline | 🟢 |
| Fund manager transparency | 🟡 |
| Investment horizon suitability | 🟡 |
| Market cap flexibility utilisation | 🟢 |
| Concentration vs diversification balance | 🔴 |
| AUM size and strategy capacity | 🟡 |
| Manager tenure and continuity risk | 🟢 |
Here is a way to think about this that goes beyond simply “good fund” or “bad fund.”
Your core portfolio should be the part of your wealth doing the steady, unglamorous work — broad, diversified, low-cost exposure through index funds, flexi-cap mutual funds, and multi-asset allocations.
It is not designed to thrill you. It is designed to compound reliably while you live your life.
Your satellite portfolio is where you take deliberate, sized bets on genuine differentiation — strategies that go where your core cannot, in proportions you have consciously decided you can afford to be wrong about.
The honest question for you is this: is ValueQuest Platinum sitting in your portfolio as a sized, deliberate satellite bet — or has it quietly become a disproportionately large slice of your overall wealth simply because it performed well and you never rebalanced?
A strategy that delivers 65.6% in one year and -7.92% in another is not behaving like a core holding, even if it has earned a place at the table.
If ₹25 crores in this single concentrated strategy represents 60% of your liquid net worth, that is a different conversation than if it represents 10%.
A satellite allocation earns its place in your portfolio when it passes a few honest tests:
A strategy can satisfy most of these criteria and still be the wrong size for your specific portfolio at this specific moment in your life.
That sizing question is worth revisiting at least once a year, particularly after a year like the one this strategy has just had.
If, after working through the Zero-Based Thinking Test, you are leaning toward reducing or exiting your position, here is what you need to know before acting.
Exit Load: 1% applies if you exit within the first three years from each tranche of investment. After three years from each respective contribution, there is no exit load.
Tax Treatment: PMS holdings sit directly in your Demat account, which means every stock-level transaction — whether triggered by the fund manager’s rebalancing or by your own exit — creates a taxable event.
Positions held over 12 months attract LTCG at 12.5%; positions held under 12 months attract STCG at 20%.
Ask your relationship manager for a stock-level, acquisition-date breakdown before initiating any exit, since your actual tax liability depends entirely on the vintage of each underlying holding, not on when you personally invested.
Staggered Exit Strategy: If a full exit would trigger a large, concentrated tax event, consider spreading the redemption across two or three financial years to manage your LTCG threshold more efficiently and avoid an unnecessarily large single-year tax bill.
Timing Note: Given the strategy’s recent -4.65% one-year performance, exiting now would mean realising losses or reduced gains on positions that have historically recovered from similar drawdown years (2018, 2021, 2022).
This is not a reason to avoid exiting if your conviction has genuinely changed — but it is a reason to make sure the decision is driven by your own risk tolerance and time horizon, not simply by recent performance anxiety.
1. Is ValueQuest Platinum a good PMS to invest in?
The data shows genuinely strong outperformance across 3-year, 5-year, 10-year, and since-inception periods, with statistically meaningful alpha (Jensen Alpha 4.44, Sharpe Ratio 0.76 vs benchmark 0.60). Whether it is “good for you” depends on your tolerance for concentration risk and volatility, given the recent -4.65% one-year return and a standard deviation higher than the benchmark.
2. What are the returns of ValueQuest Platinum PMS?
As of May 31, 2026: 1-year -4.65%, 3-year 13.61% CAGR, 5-year 15.35% CAGR, 10-year 17.71% CAGR, and since-inception (July 2014) 17.93% CAGR — against a BSE 500 TRI benchmark of -0.07%, 13.46%, 12.29%, 14.03%, and 12.69% respectively.
3. What is the minimum investment for ValueQuest Platinum?
₹25 crores.
4. What fees does ValueQuest Platinum PMS charge?
A fixed fee option of 2.5% per annum, or a variable option of 1.5% AMC fee plus 15% profit sharing above a 10% hurdle rate.
5. Is ValueQuest PMS fees worth it?
Over the 5-year and since-inception periods, the net-of-fee alpha generated (+3.06% and +5.24% respectively) suggests the fee has historically been earned. The most recent 1-2-year period does not support this same conclusion, so the answer depends heavily on which time window you evaluate.
6. How concentrated is the ValueQuest Platinum portfolio?
The stated mandate targets 8-12 core stocks, with the disclosed portfolio showing 22 holdings where the top 5 stocks represent 43.44% and the top 5 sectors represent 91.86% of the total portfolio of ValueQuest Platinum PMS.
7. What is the ValueQuest Platinum portfolio stocks list?
Top holdings include Apar Industries, Cholamandalam Investment and Finance Company, Concord Biotech, Home First Finance Company India, and Tenneco Clean Air India, with sector concentration weighted toward Capital Goods (23.93%), Pharmaceuticals & Biotechnology (17.39%), and Financial Services (14.82%).
8. How does ValueQuest Platinum PMS compare to a mutual fund or index fund?
Over a 5-year period on a ₹50 lakh allocation, this strategy’s net returns translate to roughly ₹12-15 lakhs more than a passive BSE 500 index fund and are broadly comparable to category-median active flexi-cap mutual funds, though with meaningfully higher volatility and concentration risk than either alternative.
9. How do I exit a PMS like ValueQuest Platinum?
Exit load of 1% applies to ValueQuest Platinum PMS within the first three years of each investment tranche; thereafter there is no exit load.
Since PMS holdings sit in your Demat account, exiting triggers stock-level capital gains tax (LTCG at 12.5% for holdings over 12 months, STCG at 20% for holdings under 12 months), and a staggered exit across financial years can help manage the tax impact.
10. Is PMS underperformance over 1 year a reason to exit?
Not automatically. A single difficult year inside an otherwise strong multi-year track record is common for concentrated, small-cap-oriented strategies — this strategy has seen similar drawdown years in 2018, 2021, and 2022, each followed by recovery. The more useful question is whether your own conviction, time horizon, and risk tolerance still match the strategy today, independent of any single year’s number.
Our Approach
At Holistic Financial Services, we study PMS strategies across the market — not to replace your mutual fund portfolio, but to identify the rare few that genuinely complement it.
A PMS earns its place only when it adds a return stream your existing funds cannot access, without duplicating what you already own or overwhelming your risk capacity.
If you’d like to sit down and map your ValueQuest Platinum allocation against your existing holdings and overall risk profile, we offer a complimentary portfolio review for HNI investors.
Bring your statement. We’ll tell you honestly whether this strategy’s current size and concentration still fit your portfolio — or whether it’s time to rebalance.
Listen to this article Most mutual fund investors spend considerable time selecting schemes. They compare…
Listen to this article Most people spend decades planning their careers but surprisingly little time…
Listen to this article Can the SBI Life Smart Money Back Saver Plan help you…
Listen to this article Are you looking for a financial product that can help you…
Listen to this article Have you ever wondered whether your financial plan is prepared for…
Listen to this article What Works What Doesn't Since-inception CAGR of 13.97% beats benchmark (11.46%)…